drugset
drugset / Trial / NCT06707883

A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT06707883 ↗

Phase 2 Active not recruiting 258 enrolled Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the efficacy and safety of TQC2731 injection in patients with moderate to severe chronic obstructive pulmonary disease.

Timeline

Start
2024-12-31
Primary completion
2026-12
Completion
2027-09

Drugs

EvaluationDrugModalityDoseRoute
Subject TQC2731 Monoclonal antibody — —

Indications

chronic obstructive pulmonary disease